The utility giant Southern Company has declared its latest quarterly dividend, preserving one of corporate America's most remarkable records of shareholder returns. As markets fluctuate, the company's steady income stream and undervalued stock price are drawing renewed attention from long-term investors.
Thermo Fisher Scientific reported a strong finish to 2025, with Q4 results exceeding expectations. While navigating currency volatility and tariffs, the life sciences giant highlighted growth in core biopharma sectors, strategic acquisitions like Clario, and a solid 2026 outlook.
Swiss banking giant UBS has initiated coverage on Zai Lab Limited (NASDAQ: ZLAB) with a bullish 'Buy' rating and a $35 price target, highlighting the biopharma firm's strategic pivot from a China-focused player to a burgeoning global innovation platform with a promising proprietary pipeline.
Citizens reiterates a 'Market Outperform' rating and $396 price target for BeOne Medicines (ONC), driven by robust Phase 3 trial results in gastric cancer. The firm highlights the company's strong pipeline and cash position as key growth drivers.
Goldman Sachs has upgraded BioNTech SE (NASDAQ:BNTX) from Neutral to Buy, raising its price target to $142. The firm highlights the company's pivotal role in next-generation cancer treatments, including immuno-oncology and antibody-drug conjugates (ADCs), as a major catalyst for future growth.
RBC Capital has reaffirmed its confidence in Ascendis Pharma, raising its price target following the company's ambitious 2026 strategic goals, which hinge on sustained momentum for its lead therapy and significant long-term revenue targets.
Despite a recent 6.8% pullback, AUTO1 Group SE (ETR:AG1) has delivered a staggering 239% return to its shareholders over the past three years, highlighting the potential rewards of holding through market volatility. We examine the underlying business trends and investor sentiment behind the numbers.
Sciwind Biosciences secures Chinese approval for its GLP-1 agonist Xianyida, entering a crowded but high-stakes diabetes treatment market dominated by global giants, as the country grapples with the world's largest diabetic population.
While Sligro Food Group (AMS:SLIGR) shares have seen a modest 11% rebound in recent months, long-term investors are nursing significant losses, with the stock down 46% over five years. This deep dive examines the disconnect between the company's path to profitability and its languishing share price.
Shares of data security company Rubrik have faced significant pressure, declining over 25% in the past month. While the sell-off has pushed its valuation below some fair value estimates, analysts point to stiff competition and cautious IT spending as key headwinds. We examine whether the weakness presents a buying opportunity or a sign of deeper challenges.
MTY Food Group's recent 12% dividend hike and recognition as a top pick have reignited investor interest. However, a closer look reveals a complex valuation story, with a premium P/E ratio contrasting sharply with discounted cash flow models and recent profit margin pressures.
Zillow Group (ZG) shares, hovering near $65, present a complex picture for investors. While the stock shows signs of a recent recovery, its five-year performance tells a story of significant decline, raising questions about whether current prices reflect underlying risks or hidden opportunity.
Fueled by a landmark $20 billion funding round for AI firm Anthropic, infrastructure provider IREN is seeing its strategic shift from cryptocurrency mining to AI data centers validated by investors. With a key Microsoft partnership and surging capital flows into AI, the company's stock performance reflects a broader market reassessment of its role in high-performance computing.
Despite a recent 4.9% weekly pullback, shareholders of German-listed CHAPTERS Group (ETR:CHG) have seen staggering total returns exceeding 900% since 2019, fueled by explosive revenue growth. The journey highlights the potential rewards—and risks—of investing in high-growth, pre-profit companies.
As European indices face headwinds, a select group of small-cap companies are seeing executives put their own money on the line. We examine three firms where insider buying signals conviction amidst broader uncertainty.
While long-term investing is a cornerstone strategy, the dramatic 70% share price collapse at Future PLC over five years serves as a stark reminder that time alone doesn't guarantee returns. This analysis delves beyond the headline numbers to examine the puzzling disconnect between the company's operational metrics and its market valuation.
As markets swing between hype and fundamentals, Royal KPN's consistent earnings growth and prudent governance present a compelling case for stability-focused investors in the telecom sector.
Vera Therapeutics (VERA) is drawing bullish attention from Wall Street, with multiple analysts significantly raising price targets following a key competitor's FDA approval and revised revenue forecasts for its lead drug candidate.
British Land Company PLC (LON:BLND) finds itself firmly in the hands of institutional investors, who control 88% of its shares. While this signals strong professional backing, it also raises questions about stock volatility and boardroom influence in the UK's property sector.
Clinical-stage biopharma Mineralys Therapeutics has filed its New Drug Application for lorundrostat, a potential treatment for resistant hypertension, following positive results from multiple trials. The move positions the company for a potential 2026 market entry and has drawn upgraded price targets from analysts.
